Lung Adenocarcinoma — Trials

Lung Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

231 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 52
Recruiting: 27
Ph III recruiting: 6
Growth YoY: —
Industry share: 13%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (28)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05566223	CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2)	withdrawn	Phase 1 / Phase 2	0	Intima Bioscience, Inc.INDUSTRY	1	Feb 23, 2026	clinicaltrials
NCT03361319	Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma(N3)	withdrawn	Phase 1 / Phase 2	0	Royal Marsden NHS Foundation TrustOTHER	0	Nov 24, 2020